Table 4 1-year follow-up outcome
Variables | MR-group (n = 23) | Control-group (n = 27) | p value |
|---|---|---|---|
LVEF (%), mean ± SD | 20.9 ± 4.8 | 22.5 ± 5.9 | 0.278 |
LVEDD (mm), mean ± SD | 65.7 ± 11.8 | 63.5 ± 9.7 | 0.568 |
TAPSE (mm), mean ± SD | 11.8 ± 2.9 | 13.9 ± 3.2 | 0.029 |
Residual mitral regurgitation ≥ 3, % (n) | 8 (34.8) | 2 (7.4) | 0.016 |
Tricuspid regurgitation ≥ 3, n (%) | 9 (39.1) | 2 (7.4) | 0.007 |
NYHA III–IV, n (%) | 17 (73.9) | 6 (24.0) | < 0.001 |
6 MWT (meter), mean ± SD | 363 ± 163 | 405 ± 86 | 0.316 |
Serum NT-proBNP level (pg/dl), mean ± SD | 7297 ± 10,682 | 1988 ± 1590 | 0.024 |
Serum GOT level (U/l), mean ± SD | 27.3 ± 18.7 | 28.0 ± 19.6 | 0.898 |
Serum GPT level (U/l), mean ± SD | 30.0 ± 26.2 | 25.3 ± 13.8 | 0.442 |
Serum bilirubin level (mg/dl), mean ± SD | 0.9 ± 0.6 | 0.8 ± 0.4 | 0.503 |
Serum creatinin level (mg/dl), mean ± SD | 1.8 ± 0.9 | 1.6 ± 0.4 | 0.490 |